Cross-protection against four serotypes of dengue virus in mice conferred by a Zika DNA vaccine

16Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Both Zika virus (ZIKV) and four serotypes of dengue virus (DENV1-4) are antigenically related mosquito-borne flaviviruses that co-circulate in overlapping geographic distributions. The considerable amino acid sequence homology and structural similarities between ZIKV and DENV1-4 may be responsible for the complicated immunological cross-reactivity observed for these viruses. Thus, a successful Zika vaccine needs to not only confer protection from ZIKV infection but must also be safe during secondary exposures with other flavivirus, especially DENVs. In this study, we used a Zika DNA vaccine candidate (pV-ZME) expressing the ZIKV premembrane and envelop proteins to immunize BALB/c mice and evaluated the potential cross-reactive immune responses to DENV1-4. We observed that three doses of the pV-ZME vaccine elicited the production of cross-reactive antibodies, cytokines and CD8+ T cell responses and generated cross-protection against DENV1-4. Our results demonstrate a novel approach for design and development of safe Zika and/or dengue vaccines.

Cite

CITATION STYLE

APA

Wang, R., Gao, N., Li, Y., Fan, D., Zhen, Z., Feng, K., … An, J. (2019). Cross-protection against four serotypes of dengue virus in mice conferred by a Zika DNA vaccine. Frontiers in Cellular and Infection Microbiology, 9(MAY). https://doi.org/10.3389/fcimb.2019.00147

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free